Page 187 - EJMO-9-2

Eurasian Journal of
Medicine and Oncology PD-1/L1 inhibitors in advanced CC: Multicenter retro

doi: 10.1016/s1470-2045(24)00006-8 cervical cancer. Anticancer Res. 2017;37(9):5087-5094.
21. Dietel M, Savelov N, Salanova R, et al. Real-world doi: 10.21873/anticanres.11926
prevalence of programmed death ligand 1 expression in 31. Oishi S, Kudaka W, Toita T, et al. Prognostic factors and
locally advanced or metastatic non-small-cell lung cancer: treatment outcome for patients with stage IVB cervical
The global, multicenter EXPRESS study. Lung Cancer. cancer. Anticancer Res. 2016;36(7):3471-3475.
2019;134:174-179.
32. Hunsberger KS, Tewari KS, Monk BJ, Chase DM.
doi: 10.1016/j.lungcan.2019.06.012
Standard of care treatment for stage IVB cervical cancer:
22. Vasiliadou I, Breik O, Baker H, et al. Safety and treatment A systematic review and meta-analysis. Gynecol Oncol.
outcomes of nivolumab for the treatment of recurrent 2024;191:259-264.
or metastatic head and neck squamous cell carcinoma: doi: 10.1016/j.ygyno.2024.10.023
Retrospective multicenter cohort study. Cancers (Basel).
2021;13(6):1413. 33. Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab
®
(Avastin ) in cancer treatment: A review of 15 years of
doi: 10.3390/cancers13061413
clinical experience and future outlook. Cancer Treat Rev.
23. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus 2020;86:102017.
chemotherapy for previously untreated, PD-L1-expressing, doi: 10.1016/j.ctrv.2020.102017
locally advanced or metastatic non-small-cell lung cancer
(KEYNOTE-042): A randomised, open-label, controlled, 34. Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for
phase 3 trial. Lancet. 2019;393(10183):1819-1830. advanced cervical cancer: Final overall survival and adverse
event analysis of a randomised, controlled, open-label,
doi: 10.1016/s0140-6736(18)32409-7
phase 3 trial (Gynecologic Oncology Group 240). Lancet.
24. Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant 2017;390(10103):1654-1663.
immunotherapy leads to pathological responses in MMR- doi: 10.1016/s0140-6736(17)31607-0
proficient and MMR-deficient early-stage colon cancers. Nat
Med. 2020;26(4):566-576. 35. Zhu J, Song C, Zheng Z, et al. Anlotinib in chinese patients
with recurrent advanced cervical cancer: A prospective
doi: 10.1038/s41591-020-0805-8
single-arm, open-label phase II trial. Front Oncol.
25. Reck M, Remon J, Hellmann MD. First-line immunotherapy for 2021;11:720343.
non-small-cell lung cancer. J Clin Oncol. 2022;40(6):586-597.
doi: 10.3389/fonc.2021.720343
doi: 10.1200/jco.21.01497
36. Yang H, Sun S, Mei Z, et al. A retrospective cohort study
26. Vanella V, Festino L, Vitale MG, Alfano B, Ascierto PA. evaluates clinical value of anlotinib in persistent, metastatic,
Emerging PD-1/PD-L1 antagonists for the treatment or recurrent cervical cancer after failure of first-line therapy.
of malignant melanoma. Expert Opin Emerg Drugs. Drug Des Devel Ther. 2021;15:4665-4674.
2021;26(2):79-92.
doi: 10.2147/dddt.S335870
doi: 10.1080/14728214.2021.1901884
37. Zhou M, Chen X, Zhang H, et al. China national medical
27. Shen J, Yan J, Du J, et al. Multicenter, single-arm, phase II products administration approval summary: Anlotinib
study (CAP) of radiotherapy plus liposomal irinotecan for the treatment of advanced non-small cell lung cancer
followed by camrelizumab and anti-angiogenic treatment in after two lines of chemotherapy. Cancer Commun (Lond).
advanced solid tumors. Front Immunol. 2023;14:1133689. 2019;39(1):36.
doi: 10.3389/fimmu.2023.1133689 doi: 10.1186/s40880-019-0383-7
28. Li Y, Du Y, Xue C, et al. Efficacy and safety of anti-PD-1/ 38. Liu L, Cai L, Du X, et al. Anti-tumour effect of in situ
PD-L1 therapy in the treatment of advanced colorectal vaccines combined with VEGFR inhibitors in the treatment
cancer: A meta-analysis. BMC Gastroenterol. 2022;22(1):431. of metastatic cervical cancer. Int Immunopharmacol.
2021;101(Pt B):108302.
doi: 10.1186/s12876-022-02511-7
doi: 10.1016/j.intimp.2021.108302
29. Kornprat P, Pollheimer MJ, Lindtner RA, Schlemmer A,
Rehak P, Langner C. Value of tumor size as a prognostic 39. Li AQ, Fang JH. Anti-angiogenic therapy enhances cancer
variable in colorectal cancer: A critical reappraisal. Am J immunotherapy: Mechanism and clinical application.
Clin Oncol. 2011;34(1):43-49. Interdiscip Med. 2024;2(1):e20230025.
doi: 10.1097/COC.0b013e3181cae8dd doi: 10.1002/INMD.20230025
30. Kim M, Kim H, Suh DH, et al. Identifying rational 40. Bräutigam K, Schmidt T, Baur M, et al. Prevalence of PD-L1
candidates for immunotherapy targeting PD-1/PD-L1 in in cervical cancer patients and the potential for combining

Volume 9 Issue 2 (2025) 179 doi:10.36922/ejmo.8074